| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284611 | Clinical Gastroenterology and Hepatology | 2010 | 10 Pages |
Abstract
Long-term maintenance therapy with infliximab is required to maintain mucosal integrity in patients after surgery for Crohn's disease. However, a dose of 3 mg/kg (a 40% reduction from the standard dose) was sufficient to avoid disease recurrence, determined by endoscopy, in all patients at 1 year. FC levels correlate with mucosal status at different infliximab doses.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Dario Sorrentino, Alberto Paviotti, Giovanni Terrosu, Claudio Avellini, Marco Geraci, Dimitra Zarifi,